Skip to content
DataLookout
Menu

NCT07437963

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 42 versions: 10 with changes below, 32 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 3 → 7 locations
  2. Minor Study sites: 4 to 7
  3. Minor Trial sites expanded: 0 → 3 locations
  4. Notable Primary endpoint(s) modified
    • Study sites: 2 to 3
  5. Notable Primary endpoints: 3 to 2
    • Secondary endpoints revised (5)
    • Study description shortened, about 1 word
  6. Minor Study sites: 1 to 2
  7. Notable Recruitment opened Show 4 more changesShow less
    • Start date pushed from Oct 28, 2026 to Jun 25, 2027
    • Eligibility criteria expanded, about 135 words
    • Study sites: 0 to 1
    • Secondary endpoints: details revised at 3 of 5 entries
  8. Notable Start date: Jul 30, 2026 to Oct 28, 2026v34
  9. Notable Start date: May 1, 2026 to Jul 30, 2026v32
  10. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Recommended phase 2 dose (Phase 1)
Timeframe: Up to the completion of phase 1
Response rate (Phase 2)
Timeframe: Post-randomization through the end of cycle 12 (Cycle length = 28 days)

Secondary (5)

Response rate (Phase 1)
Progression-free survival (Phase 2)
Overall survival (Phase 2)
Confirmed response rate (Phase 2)
Duration of response (Phase 2)

Arms and interventions

Phase 1 (iberdomide, CPM, Topo, DIN, GM-CSF)Experimental

Patients receive iberdomide PO, via NG-tube, or via G-tube QD on days 1-14 or 1-21, cyclophosphamide IV over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim SC or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until ANC is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo ECHO or MUGA, bone marrow aspiration and biopsy, CT or MRI, and 123I-MIBG scans or FDG-PET throughout the study. Patients also undergo blood sample collection on study.

Phase 2 arm A (CPM, Topo, DIN, GM-CSF)Active comparator

Patients receive cyclophosphamide IV over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim SC or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until ANC is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo ECHO or MUGA, bone marrow aspiration and biopsy, CT or MRI, and 123I-MIBG scans or FDG-PET throughout the study. Patients also undergo blood sample collection on study.

Phase 2 arm B (iberdomide, CPM, Topo, DIN, GM-CSF)Experimental

Patients receive iberdomide PO, via NG-tube, or via G-tube QD on days 1-14 or 1-21, as determined in phase 1, cyclophosphamide IV over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim SC or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until ANC is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo ECHO or MUGA, bone marrow aspiration and biopsy, CT or MRI, and 123I-MIBG scans or FDG-PET throughout the study. Patients also undergo blood sample collection on study.

Procedures: Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Multigated Acquisition Scan

Drugs: Cyclophosphamide, Iberdomide, Topotecan

Biologicals: Dinutuximab, Sargramostim

Radiation: Nuclear Radiology Imaging Procedure

Sites

8 sites in 1 country